A continuous glucose monitoring device that resides fully in the subcutaneous tissue has the potential to greatly improve the management of diabetes. Toward this goal, we have developed a competitive binding glucose sensing assay based on fluorescently labeled PEGylated concanavalin-A (PEGylated-TRITC-ConA) and mannotetraose (APTS-MT). In the present work, we sought to contain this assay within the hollow central cavity of a cylindrical hydrogel membrane, permitting eventual subcutaneous implantation and optical probing through the skin. A "self-cleaning" hydrogel was utilized because of its ability to cyclically deswell/reswell in vivo, which is expected to reduce biofouling and therefore extend the sensor lifetime. Thus, we prepared a hollow, cylindrical hydrogel based on a thermoresponsive electrostatic double network design composed of N-isopropylacrylamide and 2-acrylamido-2-methylpropanesulfonic acid. Next, a layer-by-layer (LbL) coating was applied to the inner wall of the central cavity of the cylindrical membrane. It consisted of 5, 10, 15, 30, or 40 alternating bilayers of positively charged poly(diallyldimethylammonium chloride) and negatively charged poly(sodium 4-styrenesulfonate). With 30 bilayers, the leaching of the smaller-sized component of the assay (APTS-MT) from the membrane cavity was substantially reduced. Moreover, this LbL coating maintained glucose diffusion across the hydrogel membrane. In terms of sensor functionality, the assay housed in the hydrogel membrane cavity tracked changes in glucose concentration (0 to 600 mg/dL) with a mean absolute relative difference of ∼11%.
A continuous glucose monitoring device that resides fully in the subcutaneous tissue has the potential to greatly improve the management of diabetes. Toward this goal, we have developed a competitive binding glucose sensing assay based on fluorescently labeled PEGylated concanavalin-A (PEGylated-TRITC-ConA) and mannotetraose (APTS-MT). In the present work, we sought to contain this assay within the hollow central cavity of a cylindrical hydrogel membrane, permitting eventual subcutaneous implantation and optical probing through the skin. A "self-cleaning" hydrogel was utilized because of its ability to cyclically deswell/reswell in vivo, which is expected to reduce biofouling and therefore extend the sensor lifetime. Thus, we prepared a hollow, cylindrical hydrogel based on a thermoresponsive electrostatic double network design composed of N-isopropylacrylamide and 2-acrylamido-2-methylpropanesulfonic acid. Next, a layer-by-layer (LbL) coating was applied to the inner wall of the central cavity of the cylindrical membrane. It consisted of 5, 10, 15, 30, or 40 alternating bilayers of positively charged poly(diallyldimethylammonium chloride) and negatively charged poly(sodium 4-styrenesulfonate). With 30 bilayers, the leaching of the smaller-sized component of the assay (APTS-MT) from the membrane cavity was substantially reduced. Moreover, this LbL coating maintained glucose diffusion across the hydrogel membrane. In terms of sensor functionality, the assay housed in the hydrogel membrane cavity tracked changes in glucose concentration (0 to 600 mg/dL) with a mean absolute relative difference of ∼11%.
Diabetes mellitus affects
more than 29 million people in the U.S.
and over 300 million people worldwide.[1] Tight glycemic control is of critical importance, as hyper- and
hypoglycemic states can lead to short and long-term complications
as well as morbidity.[1,2] The commonly used finger-prick
test provides only intermittent monitoring and is associated with
poor testing compliance stemming from its inconvenience and discomfort.
Continuous glucose monitors (CGMs), by providing real-time glycemic
monitoring, have the potential to improve diabetes management and
health outcomes.[3−5] Current FDA-approved CGMs are based on an electroenzymatic
sensor consisting of a needle-type probe comprised of an electrode
and embedded glucose oxidase enzyme. The probe is transdermally inserted,
and the glycemic level in the interstitial fluid (ISF) is monitored
via amperometric signals from the glucose oxidation reaction. While
some newer CGMs have eliminated finger-prick test calibrations, the
sensors must be replaced every 7–10 days. Their transdermal
nature is required for frequent removal and replacement but also is
associated with irritation and infection at the insertion site.[6] A CGM that could achieve a longer lifetime and
thus be implanted fully subcutaneously would represent a significant
advancement. To achieve this, progress must be made to improve glucose
sensing as well as to reduce sensor biofouling. Toward the realization
of a subcutaneous CGM, we have conducted independent studies on an
optical glucose sensing assay and a self-cleaning sensor membrane
as described below and in Figure .
Figure 1
(a) Fluorescent competitive binding assay based on PEGylated-TRITC-ConA
and APTS-MT. (b) Cross-section of self-cleaning membrane “cylinder”
with a hollow cavity. (c) LbL coating applied to the membrane cavity
wall to inhibit diffusion of the assay components from the cavity.
(a) Fluorescent competitive binding assay based on PEGylated-TRITC-ConA
and APTS-MT. (b) Cross-section of self-cleaning membrane “cylinder”
with a hollow cavity. (c) LbL coating applied to the membrane cavity
wall to inhibit diffusion of the assay components from the cavity.Optical glucose biosensors are
advantageous over electrochemical
sensors because they do not rely on the placement of a transducer
or other hardware components in direct contact with the specimen during
sensing, thereby allowing for the potential development of non- or
minimally invasive biosensors. Various optical glucose monitoring
approaches have been reviewed in the literature.[7−9] Those based
on the use of optical modalities include Raman spectroscopy,[10−14] optical coherence tomography (OCT),[15,16] photoacoustic
spectroscopy,[17−19] optical polarimetry,[20−24] infrared spectroscopy,[25,26] and fluorescence
spectroscopy.[27−31]Competitive binding assays to track glucose levels using Förster
resonance energy transfer (FRET) as the transduction mechanism that
are based on concanavalin A (ConA) (a glucose receptor) and a glucose-like
competing ligand have been described.[32−37] At pH 7.4, ConA comprises four identical monomeric subunits,[38] each of which has a single carbohydrate binding
site. ConA is able to reversibly bind to glucose (with high affinity)
and a fluorescently labeled competing ligand (presenting multiple
low-affinity moieties) (e.g., fluorescein isothiocyanate (FITC)-dextran).
Thus, changes in the fluorescence signal at equilibrium can be used
to observe the concentration of glucose. However, these assays are
prone to aggregation in free solution, a result of extensive cross-linking
between the multiple binding sites of ConA and the multivalent competing
ligand, as well as the inherent thermal instability of ConA.[31,39,40] Thus, we recently reported the
use of a new type of competing ligand, aminopyrene trisulfonate mannotetraose
(APTS-MT), which presents a single high-affinity trimannose moiety
that utilizes the full binding site of ConA and thus avoids aggregation.[41] Additionally, we demonstrated that tethering
of poly(ethylene glycol) (PEG) to ConA (i.e., PEGylation) improved
ConA’s thermal stability and resistance to electrostatic binding.[42] Finally, we demonstrated improved FRET efficiency
leading to enhanced sensitivity to changes in glucose levels.[43] Compared with APTS-dextran, the close proximity
of APTS-MT’s core trimannose structure and donor fluorophore
decreases the distance between the FRET donor and FRET acceptor on
ConA to maximize the FRET efficiency upon binding of the ligand to
ConA. Thus, as the glucose concentration increases, the ratio of the
fluorescence intensities of the two dyes (520 to 580 nm) would be
expected also to increase because of an increase in the Förster
radius during the competition between glucose and APTS-MT for the
binding sites of ConA (Figure a). Thus, in free solution the FRET efficiency of the assay
increased from ∼25% with APTS-dextran to ∼89% with APTS-MT
across the physiologically relevant glucose range and thus had 4 times
more sensitivity.[43] This PEGylated-TRITC-ConA/APTS-MT
assay in free solution also displayed a mean absolute relative difference
(MARD) of 5% across the physiologically relevant glucose concentration
range.We have also previously described “self-cleaning”
membranes directed at reducing biofouling on implanted glucose biosensors
(Figure b).[44−46] These membranes are based on poly(N-isopropylacrylamide)
(PNIPAAm) hydrogels, which are known to undergo reversible deswelling/reswelling
when cycled above/below their volume phase transition temperature
(VPTT).[47,48] This process has been applied to thermally
control the removal of cultured cells in vitro.[49−51] Transdermal
heating/cooling or body temperature fluctuations may affect thermal
cycling of such an implanted membrane. Most recently, we reported
double network (DN) thermoresponsive membranes that incorporated a
negatively charged comonomer, 2-acrylamido-2-methylpropane sulfonic
acid (AMPS), to improve the mechanical robustness.[46,52] Specifically, these DN hydrogels consist of a tightly cross-linked,
negatively charged first network [P(NIPAAm-co-AMPS)]
containing variable levels of AMPS (NIPAAm:AMPS weight ratio = 100:0
to 25:75) and a loosely cross-linked, interpenetrating second network
[PNIPAAm]. In addition, N-vinylpyrrolidone (NVP)
(∼15 wt % based on NIPAAm weight) was incorporated into the
second network to increase the DN VPTT from ∼35 to ∼38
°C. Thus, when implanted into the subcutaneous tissue, this P(NIPAAm-co-AMPS)/P(NIPAAm-co-NVP) DN membrane would
be quite swollen (to maximize glucose diffusion) but cyclical increases/decreases
in the temperature of the tissue would cause relative deswelling/reswelling
of the membrane to limit cell attachment and to remove adhered cells,
as was demonstrated in vitro. Additionally, these membranes demonstrated
increased modulus and strength as well as glucose diffusion coefficients
(D = 1.8–2.2 × 10–6 cm2/s) in the functional range for dermal and epidermal
tissues (D = (2.64 ± 0.42) × 10–6 and (0.075 ± 0.05) × 10–6 cm2/s, respectively).[53]In this work,
we sought to house the fluorescent competitive binding
assay within the hollow cavity of a cylindrical self-cleaning membrane,
toward creating a subcutaneous CGM with long-term efficacy (Figure c). The P(NIPAAm-co-AMPS)/P(NIPAAm-co-NVP) DN membrane was
prepared with a cylindrical geometry (∼5 mm × ∼2.5
mm, length × diameter), conducive to implantation via simple
subcutaneous injection, and with a hollow central cavity (diameter
= 600 μm; volume = 1 μL) to house the assay. As shown
herein, the mesh size of the membrane exceeded that of the APTS-MT
assay component, leading to its rapid leaching from the central cavity.
Thus, we evaluated the ability of a layer-by-layer (LbL) coating applied
to the surface of the membrane cavity to limit assay diffusion but
still permit glucose diffusion. LbL coatings have been explored as
semipermeable diffusion barriers on drug-containing microspheres and
microcapsules.[54−57] Additionally, LbL coatings have been applied to temporary calcium
carbonate microsphere templates containing embedded optical sensing
assays for the detection of oxygen, glucose, and urea.[58−61] However, this approach presents challenges in terms of dissolving
the template and achieving optimal loading efficiency of the assay.
In contrast, the approach reported here, in which the assay is directly
housed in a hollow cavity of a membrane rather than loaded onto a
template, provides a route for more efficient loading and control
of the assay concentration.Herein we report the use of a LbL
coating to inhibit the leaching
of a fluorescent competitive binding assay (mPEG-TRITC-ConA/APTS-MT)
from the central cavity of a PNIPAAm-based self-cleaning membrane.
The negative charge of the P(NIPAAm-co-AMPS)/P(NIPAAm-co-NVP) DN membrane, stemming from the highly ionized nature
of the AMPS comonomer,[62] provided an excellent
substrate on which to build a LbL coating. The LbL coating comprised
bilayers of positively charged poly(diallyldimethylammonium chloride)
(PDADMAC+) and negatively charged poly(sodium 4-styrenesulfonate)
(PSS–). The extent of assay leaching and rate of
glucose diffusion as functions of the number of PDADMAC+/PSS– bilayers (5, 10, 15, 30, or 40) were investigated.
Additionally, biosensors (i.e., assay-loaded membranes) were evaluated
for their sensitivity to track glucose levels across a physiological
range.
Materials and Methods
Materials
NIPAAm (97%), AMPS (97%),
NVP, PEG-DA (∼99%; Mn = 575 g/mol),
Trizma hydrochloride (Trizma-HCl), manganese(II) chloride (MnCl2), sodium bicarbonate, methyl α-d-mannopyranoside
(MaM), PDADMAC+ solution (MW = 100–200 kDa), PSS– (MW ≈ 70 kDa), and FITC-dextran (MW = 4, 10,
20, or 40 kDa) were obtained from Sigma-Aldrich (St. Louis, MO). Rhodamine
B isothiocyanate poly(allylamine hydrochloride) (RITC-PAH+) was prepared by reacting PAH hydrochloride (MW = 15 kDa) and RITC
at a RITC:PAH molar ratio of 20:1 per analogous reports.[63]N,N′-Methylenebis(acrylamide)
(BIS) (99%) was purchased from Acros. 2-Hydroxy-2-methyl-1-phenylpropan-1-one
(DAROCUR 1173) was purchased from Ciba Specialty Chemicals (Basel,
Switzerland). 1-[4-(2-Hydroxyethoxy)phenyl]-2-hydroxy-2-methylpropan-1-one
(Irgacure 2959) was purchased from BASF. Calcium chloride dihydrate
(CaCl2) was purchased from J.T. Baker (Center Valley, PA).
Sodium chloride (NaCl) was obtained from Mallinckrodt Chemical (St.
Louis, MO). Methoxyl-poly(ethylene glycol)-N-hydroxylsuccinimide-succinimidyl
carbonate (mPEG-NHS (SC), 5 kDa) was purchased from Nanocs (New York,
NY). Anhydrous dextrose (d-glucose) was purchased from Fisher
Scientific (Pittsburgh, PA). ConA labeled with tetramethylrhodamine
fluorescent dye (TRITC-ConA) and RITC was purchased as a lyophilized
powder from Life Technologies (Grand Island, NY). The Tris-buffered
saline (TBS) (pH 7.4, 10 mM Trizma-HCl, 0.15 M NaCl, 1 mM MnCl2, and 1 mM CaCl2) and 0.1 M sodium bicarbonate
buffer (pH 8.5, 0.15 M NaCl) were prepared with deionized (DI) water
(18 MΩ cm). Glass beads (710–850 μm diameter) were
purchased from Cospheric LLC (Santa Barbara, CA). The dialysis membrane
tubes (20 kDa molecular weight cutoff) were purchased from Spectrum
Laboratories (Rancho Dominguez, CA).
Synthesis of Assay Components
PEGylated-TRITC-ConA
and APTS-MT were prepared according to our prior reports.[41,42] In this way, PEGylated-TRITC-ConA was formed with an average of
∼5 mPEG chains grafted per ConA monomer.[42]
Membrane Fabrication
The “first
network precursor solution” was formed with NIPAAm and AMPS
monomer (NIPAAm:AMPS weight ratio = 75:25, total weight = 1.0 g),
BIS cross-linker (0.04 g), Irgacure 2959 photoinitiator (0.08 g),
and DI water (7.0 mL). The “second network precursor solution”
was formed by combining NIPAAm (6.0 g), NVP (0.96 g), BIS (0.012 g),
Irgacure 2959 (0.24 g), and DI water (21.0 mL).
Planar Sheets
Planar sheets (∼1.5 mm thickness)
were prepared by pipetting the first network precursor solution into
a rectangular mold consisting of two glass slides separated by 1 mm
thick Teflon spacers. The mold was immersed in an ice–water
bath and exposed for 30 min to UV light (UV transilluminator, 6 mW
cm–2, 365 nm). The resulting single network (SN)
hydrogel was removed from the mold, soaked in DI water for 2 days,
and then transferred to the second network precursor to soak for 2
days at 4 °C. The hydrogels were then sandwiched between two
glass slides with 1.25 mm thick Teflon spacers enclosing the edges
for support. The molds were immersed in an ice–water bath and
exposed for 30 min to UV light. The DN hydrogels were removed from
the mold and soaked in DI water as before. These specimens were used
to measure glucose diffusion.
Hollow Cylindrical Rods
Hollow cylindrical SN rods
were prepared by pipetting the first network solution into a cylindrical
glass mold (outer diameter = 1 mm, length = 10 mm) fitted with custom
Teflon end caps to secure a steel wire (diameter = 300 μm) through
the center of the mold and to seal the mold. The mold was immersed
in an ice–water bath and exposed for 30 min to UV light as
above. To remove the SN hydrogel rods, the Teflon caps were detached,
and the molds were heated in an oven (∼1 h at 120 °C)
to dehydrate and subsequently shrink the rods so that they easily
slid out of the mold intact. The SN hydrogels were soaked in DI water
for 2 days at room temperature and then transferred into the second
network precursor solution for 2 days at 4 °C. Next, a steel
wire (∼500 μm diameter, representing the new cavity diameter
of ∼600 μm postswelling) was inserted into the hollow
cavity. The construct was wrapped in transparent plastic wrap (Saran),
submerged in an ice–water bath, exposed for 10 min to UV light,
and finally soaked in DI water as above. The steel wire was removed,
and a clean razor blade was used to trim the ends, resulting in hollow
rods (5 mm × 2.5 mm × 600 μm, length × outer
diameter × inner diameter).
Membrane
Mesh Size
Discs (∼13
mm diameter) were harvested from the uncoated hydrogel slabs (∼1.5
mm thickness) with a biopsy punch. Each disc was immersed in 0.01
mg/mL FITC-dextran solution for 2 days and then rinsed with DI water,
blotted with a Kimwipe, and placed in 1 mL of DI water. The fluorescence
intensity of the DI water (due to diffusion of FTIC-dextran from the
disc) was monitored at different time points (5 min, 24 h, and 48
h) starting from the time the sample was placed in DI water. The percent
intensity ratio (%I) was determined by eq ,in which IDI is
the intensity of DI water at a given time point and Istock is the intensity of the 0.01 mg/mL stock solution.
A %I value of <5% indicated that a trace amount
of FTIC-dextran could diffuse into the sample, indicating that the
particular FTIC-dextran was larger than the hydrogel’s mesh
size.
Hydrodynamic Radii of Assay Components
The hydrodynamic radii of PEGylated-TRITC-ConA and APTS-MT were previously
determined to be ∼15 and ∼1–2 nm, respectively,
via dynamic light scattering measurements.[41,42] The hydrodynamic radius of glucose is reported to be ∼0.4
nm.[64]
Deposition
of an LbL Coating onto the Inner
Cavity Walls of Membrane Rods and onto Planar Slabs
The polyelectrolytes
PDADMAC+, PSS–, and RITC-PAH+ were prepared at pH 8 in 5 mM sodium bicarbonate buffer at a concentration
of 2 mg/mL. The hollow membrane rod was connected to the inlet and
outlet needles (gauge = 30), which were then connected via Teflon
tubing (i.d. = 1/32″) to a plastic syringe
with the designated polyelectrolyte solution or DI water. The syringe
was used to dispense 1 mL of solution into the hollow rod cavity,
and the solutions were sequentially rinsed through the cavity with
short (∼1 min) delays between: DI water (5 mL, 3×), positively
charged polyelectrolyte (1 mL, 1×), DI water (5 mL, 1×),
negatively charged polyelectrolyte (1 mL, 1×) and DI water (5
mL, 1×). After all of the bilayers had been deposited, the cavity
was rinsed again with DI water (5 mL, 3×). The portions of the
rods that were not coated because the needle was present were cut
off, giving a final rod length of 5 mm. Separate rods were deposited
with a fluorescently labeled positive layer (RITC-PAH+)
instead of PDADMAC+ to image and evaluate the success of
the inner wall coating of the polyelectrolytes. For these images,
LbL coating (RITC-PAH+/PSS–) of six bilayers
was used, and confirmation of the deposition was evaluated with bright-field
and fluorescence images (Nikon Eclipse TE2000-U Inverted Microscope,
Nikon Instruments, Melville, NY). For all of the other experiments,
the LbL coating (PDADMAC+/PSS–) was likewise
applied at 5, 15, 30, or 40 bilayers.LbL-coated planar slabs,
designated for glucose diffusion tests, were likewise prepared. Specimens
(1 cm × 1 cm) were placed in an open-face filter holder (Pall
Co., Port Washington, NY) with one “face” exposed for
successive treatment with the designated solutions as described above.
The treated specimens were removed and permitted to soak in DI water
for 24 h prior to glucose diffusion tests.
Glucose
Diffusion Tests
Planar membrane
slabs previously coated LbL with 0, 10, 20, or 30 PDADMAC+/PSS– bilayers were subjected to glucose diffusion
tests performed at 35 °C (i.e., the subcutaneous temperature
of the wrist in humans[65]). A specimen (1
cm × 1 cm) was placed in a side-by-side diffusion chamber setup
(PermeGear, Bethlehem, PA) with the LbL-coated side facing the receiver
chamber containing 3 mL of DI H2O. The donor chamber contained
3 mL of glucose solution (1000 mg/dL). The chambers were mounted on
a stir plate set to 1000 rpm to ensure that the concentrations in
both chambers remained uniform. The diffusion chambers were connected
to a water bath pump system set to 35 °C. At 20 min intervals
for a period of 3 h, 50 μL of solution was extracted from each
chamber via a pipet, and the glucose concentration was determined
(YSI 2300 Stat Plus biochemistry analyzer, YSI Inc., Yellow Springs,
OH).The diffusion coefficient was calculated using the following
derivative form of Fick’s second law of diffusion (eq ):where c is the concentration
within the receiving chamber, t is the time, D is the diffusion coefficient, and x is
the diffusion distance.[45,66,67] Under the assumption that each chamber maintained a uniform concentration, eq was simplified to eq :[45]where Q is the amount of glucose transferred through the
membrane
at a specific time t, A is the area
of the hydrogel exposed to either the donor or receiver chamber, Ci is the initial stock glucose concentration
within the donor channel at t = 0, and T is the thickness of the hydrogel membrane.
Assay
Leaching from the Assay-Containing Membrane
(“Biosensor”)
The cavity of a hollow membrane
rod (5 mm × 2.5 mm × 600 μm, length × outer diameter
× cavity diameter) that had previously been coated with 0, 5,
15, 30, or 40 PDADMAC+/PSS– bilayers
was filled with 1 μL of the glucose sensing assay solution.
The assay solution consisted of 10 μM mPEG-TRITC-ConA and 2
μM APTS-MT prepared in TBS. After injection of the assay via
the open cavity, each end of the hollow cavity was first capped with
a glass bead and then secured by applying ∼0.5 μL of
a PEG-DA solution (575 g/mol; ∼99 wt %) and cured by exposure
to UV light (20 s). The sealed rods were thoroughly rinsed with DI
water. Each resulting “biosensor” was individually submerged
in 150 μL of TBS solution inside a 200 μL PCR centrifuge
tube. After 10 min, a small volume of high-concentration glucose solution
(glucose dissolved in TBS) was pipetted into the tube to achieve a
final glucose concentration of 1000 mg/dL, and the sealed tube (additionally
wrapped with Parafilm) was incubated at room temperature. After 24
h, 50 μL of the supernatant surrounding a biosensor was removed
and transferred to a microplate reader, and fluorescence measurements
were recorded (Tecan microplate reader; excitation wavelength (λex) = 450 nm; emission wavelength (λem) scan
range = 480 to 680 nm). The emission peak at ∼520 nm was recorded
as it pertained to the presence of APTS-MT in the supernatant. Three
different biosensors with the designated number of bilayers were used
for these measurements.Next, a more in depth leaching study
of both assay components was conducted for biosensors coated LbL with
0 or 30 PDADMAC+/PSS– bilayers. Biosensors
were likewise prepared and individually submerged in 150 μL
of glucose solution (1000 mg/dL) inside a 200 μL PCR centrifuge
tube. After 1 h, 50 μL of the supernatant surrounding a biosensor
was removed and transferred to a microplate reader, and fluorescence
measurements were recorded (Tecan microplate reader, λex = 450 nm, λem range = 480 to 680 nm). The peak
emissions at ∼520 and ∼580 nm, indicative of the presence
of APTS-MT and PEGylated-TRITC-ConA, respectively, were recorded.
The supernatant was then transferred back to the respective PCR tubes.
Fluorescence measurements were repeated at times of 2, 3, 4, 5, 8,
and 12 h. Three different biosensors with the designated number of
bilayers were used for these measurements. To determine the corresponding
percent loss of each assay component, 1 μL of the glucose sensing
assay solution was pipetted directly into 150 μL of 1000 mg/dL
glucose solution in TBS to simulate complete leaching of the assay
from the membrane cavity. Then 50 μL of this free assay solution
was subjected to fluorescence measurements as above (APTS-MT: λex= 450 nm, λem = 480 to
600 nm, peak λem ≈ 520 nm; PEGylated-TRITC-ConA:
λex = 540 nm, λem = 560 to 620 nm,
peak λem ≈ 580 nm). The percent lost was calculated
as the ratio of the measured peak emission for each assay component
present in the biosensor’s supernatant and the initial intensity
for each assay component from the above free assay solution measurement.
Glucose Response of the Assay-Containing Membrane
(“Biosensor”)
An initial 24 h glucose response
study was conducted for biosensors whose hollow cavity was coated
LbL with 0, 5, or 30 PDADMAC+/PSS– bilayers.
Each biosensor was individually placed horizontally in a 96-well plate
(Greiner Bio-One), and 200 μL of TBS solution was pipetted into
each well. After 10 min, fluorescence measurements were recorded (Tecan
microplate reader, λex = 450 nm, λem range = 480 to 680 nm), and the FRET ratio (520 nm:600 nm) was recorded
as noted above. Next, the biosensor was transferred to a 200 μL
PCR centrifuge tube containing 150 μL of high glucose concentration
(1000 mg/dL) solution. After 24 h, fluorescence measurements were
again taken, and the FRET ratio was likewise recorded. Three different
biosensors with the designated number of bilayers were used for these
measurements.Next, a temporal glucose response study was likewise
conducted for biosensors whose cavities were coated LbL with 30 PDADMAC+/PSS– bilayers and exposed to physiologically
relevant glucose levels (50–600 mg/dL). A given biosensor was
progressively transferred to the well containing a solution of the
next highest glucose concentration. After 15 min, the FRET ratio (520
nm:600 nm) was recorded. To determine the percent MARD, the FRET ratio
was then plotted as a function of the glucose concentration and fitted
to a standard competitive binding curve based on the Boltzmann equation.
Three different biosensors were used for these measurements.
Statistical Analysis
All of the
data results are reported as mean ± standard deviation. For each
set of data, mean values were compared via GraphPad Prism using analysis
of variance (ANOVA) followed by a Tukey post hoc test to determine p values.
Results and Discussion
Mesh Size of Self-Cleaning
DN Membrane
The thermoresponsive,
electrostatic P(NIPAAm-co-AMPS)/P(NIPAAm-co-NVP) DN membrane was previously shown to exhibit resistance
to cell adhesion and accumulation and to display robust mechanical
properties.[46,52] The mesh size of the membrane
was evaluated herein and determined to be ∼6.5 to 10 nm. The
hydrodynamic radius of PEGylated-TRITC-ConA (∼15 nm)[42] thus exceeds the membrane mesh size, and thus,
PEGylated-TRITC-ConA was not anticipated to diffuse from the membrane
cavity and through the membrane wall. However, diffusion of APTS-MT
would be expected on the basis of its much lower hydrodynamic radius
(∼1–2 nm).[36] Thus, to prevent
leaching of the assay from the hollow cavity of the membrane, we proceeded
with application of LbL coatings onto the cavity wall.
Imaging of
an LbL Coating Applied to a Membrane Hollow Cavity
Wall
To confirm the ability of an LbL coating to line the
inner cavity wall of the DN membrane rod, six bilayers of a fluorescently
labeled PAH+ (RITC-PAH+) and PSS– were applied. The fluorescence images distinctly confirm the presence
of the fluorescent LbL coating (Figure ). Thus, the negative charge stemming from the AMPS
comonomer of the DN membrane provided the necessary charged substrate
on which the initial, positively charged polyelectrolyte layer (RITC-PAH+) could be applied, and the LbL coating withstood successive
washes with DI water. Moreover, the corresponding bright-field image
shows the absence of fluorescence within the middle and outer parts
of the walls of the membrane, confirming that the polyelectrolytes
did not appreciably diffuse into the membrane walls (Figure , inset).
Figure 2
Side-view fluorescent
image of a DN membrane cylinder (∼600
μm cavity diameter) with a RITC-PAH+/PSS– LbL coating applied to the cavity wall (scale bar = 500 μm).
The inset is the corresponding bright-field image showing localization
of the LbL coating on the cavity wall.
Side-view fluorescent
image of a DN membrane cylinder (∼600
μm cavity diameter) with a RITC-PAH+/PSS– LbL coating applied to the cavity wall (scale bar = 500 μm).
The inset is the corresponding bright-field image showing localization
of the LbL coating on the cavity wall.
Glucose Diffusion Test
To determine whether the presence
of the LbL coatings hindered glucose diffusion, studies were conducted
on planar DN membranes coated with 0, 10, 20, or 30 PDADMAC+/PSS– bilayers. As shown in Figure , there were no statistical differences in
the measured glucose diffusion coefficients. This is attributed to
the small hydrodynamic radius of glucose (∼0.4 nm).[64]
Figure 3
Glucose diffusion coefficients of DN membranes coated
with varying
numbers of PDADMAC+/PSS– bilayers. #, p > 0.05.
Glucose diffusion coefficients of DN membranes coated
with varying
numbers of PDADMAC+/PSS– bilayers. #, p > 0.05.
Leaching of APTS-MT versus Number of Bilayers
Biosensors
were created by coating the hollow cavities of DN membrane rods with
0, 5, 15, 30, or 40 PDADMAC+/PSS– bilayers
and subsequently filling the cavities with 1 μL of the glucose
sensing assay solution. Each biosensor was submerged in a solution
with a high glucose concentration (1000 mg/dL). This high concentration
of glucose leads to the unbound states of PEGylated-TRITC-ConA and
APTS-MT (Figure a)
and thus maximizes the potential of assay components to diffuse through
the membrane. As noted above, in the unbound state only APTS-MT was
expected to be able to diffuse through the membrane. Thus, for initial
fluorescence measurements of the liquid surrounding each biosensor,
the emission peak at ∼520 nm was recorded at 24 h to detect
APTS-MT that had leached from the cavity (Figure ). The fluorescence intensity of APTS in
the supernatant surrounding the biosensor progressively decreased
as the number of PDADMAC+/PSS– bilayers
increased from 5 to 15 and 30 but did not decrease significantly further
with 40 bilayers.
Figure 4
Normalized fluorescence (λem ≈
520 nm)
due to APTS of APTS-MT in the supernatant surrounding assay-filled
biosensors following 24 h exposure to a solution with a high glucose
concentration (1000 mg/dL). ****, p < 0.0001;
**, p = 0.001–0.01; #, p >
0.05.
Normalized fluorescence (λem ≈
520 nm)
due to APTS of APTS-MT in the supernatant surrounding assay-filled
biosensors following 24 h exposure to a solution with a high glucose
concentration (1000 mg/dL). ****, p < 0.0001;
**, p = 0.001–0.01; #, p >
0.05.On the basis of their superior
retention of the APTS-MT assay component,
biosensors with 30 bilayers were evaluated intermittently over a period
of 12 h when exposed to 1000 mg/dL glucose solution. The fluorescence
at both λem ≈ 520 nm and λem ≈ 580 nm from the supernatant surrounding a biosensor were
recorded to detect the presence of APTS-MT and PEGylated-TRITC-ConA,
respectively. On the basis of a hydrodynamic radius (∼15 nm)
that exceeds the membrane’s mesh size (∼6.5 to 10 nm),
mPEG-TRITC-ConA was retained even in the absence of the LbL coating
(Figure a).
Figure 5
Cumulative
fluorescence of the supernatant surrounding assay-filled
biosensors (whose cavities were coated with 0 or 30 bilayers) during
12 h exposure to a solution of high glucose concentration (1000 mg/dL):
(a) normalized fluorescence (λem ≈ 580 nm)
due to TRITC of PEGylated-TRITC-ConA and (b) normalized fluorescence
(λem ≈ 520) due to APTS of APTS-MT. ****, p < 0.0001; *, p = 0.01–0.05;
#, p > 0.05.
Cumulative
fluorescence of the supernatant surrounding assay-filled
biosensors (whose cavities were coated with 0 or 30 bilayers) during
12 h exposure to a solution of high glucose concentration (1000 mg/dL):
(a) normalized fluorescence (λem ≈ 580 nm)
due to TRITC of PEGylated-TRITC-ConA and (b) normalized fluorescence
(λem ≈ 520) due to APTS of APTS-MT. ****, p < 0.0001; *, p = 0.01–0.05;
#, p > 0.05.Over all of the time points, it was calculated that less
than 6%
of the PEGylated-TRITC-ConA housed in the biosensor cavity had leached
through the membrane wall and into the surrounding supernatant. In
contrast, because of its very low hydrodynamic radius (∼1–2
nm), APTS-MT readily diffused from the uncoated biosensor cavity,
with the level increasing progressively over 12 h (Figure b). This diffusion resulted
in losses of 13% and 64% of APTS-MT at 1 and 12 h, respectively. However,
for a biosensor whose cavity was coated with 30 bilayers, diffusion
of APTS-MT was substantially diminished, leading to losses of 4% and
24% after 1 and 12 h.
Glucose Response of Biosensors
The
potential impact
of the LbL coating on the glucose responsivity of the biosensor was
initially evaluated by comparing the FRET ratios of biosensors with
no bilayers (“0 bilayers”) and low (“5 bilayers”)
and high (“30 bilayers”) numbers of bilayers applied
to the cavity wall before and after 24 h exposure to a solution with
a high glucose concentration (Figure ). Upon exposure to a high glucose level, the FRET
response of the assay system should increase (Figure a). However, for biosensors with 0 or 5 bilayers,
this was not observed. On the basis of the glucose diffusion studies,
an LbL coating (even at 30 bilayers) does not inhibit glucose diffusion
through the membrane (Figure ). Thus, this compromised FRET response can be attributed
to the loss of APTS-MT from the biosensors whose cavities were coated
with 0 or 5 bilayers (Figures and 5b). In contrast, because of its
retention of APTS-MT, a biosensor whose cavity was coated with 30
bilayers exhibited the expected increase in FRET response.
Figure 6
FRET intensity
ratios of assay-filled biosensors whose cavities
were coated with 0, 5, or 30 bilayers upon exposure to 0 or 1000 mg/dL
glucose solutions for 24 h. *, p = 0.01–0.05;
#, p > 0.05.
FRET intensity
ratios of assay-filled biosensors whose cavities
were coated with 0, 5, or 30 bilayers upon exposure to 0 or 1000 mg/dL
glucose solutions for 24 h. *, p = 0.01–0.05;
#, p > 0.05.Because of its retention of APTS-MT and subsequent increased
FRET
response to high glucose levels, biosensors with 30 bilayers were
sequentially exposed to increasing physiologically relevant glucose
concentrations (50 to 600 mg/dL) for 15 min intervals (Figure ). Across this range, the biosensors
exhibited the expected progressive increase in FRET response, indicating
their responsivity to different glucose levels after only short time
intervals.
Figure 7
FRET intensity ratio of assay-filled biosensors whose cavities
were coated with 30 bilayers upon exposure to increasing physiologically
relevant glucose concentrations (0 to 600 mg/dL) for 15 min intervals.
FRET intensity ratio of assay-filled biosensors whose cavities
were coated with 30 bilayers upon exposure to increasing physiologically
relevant glucose concentrations (0 to 600 mg/dL) for 15 min intervals.For these biosensors with 30 bilayers,
the % MARD was determined
by plotting the FRET ratio as a function of the glucose concentration
and fitting to a standard competitive binding curve (Figure ). The results indicated that
these biosensors are able to track changes in glucose concentration
across the physiologic range with a MARD of 11 ± 0.9%. Our group
has previously reported that the glucose response of this assay in
free solution resulted in a MARD of ∼5% across a physiological
relevant glucose range.[43] While the % MARD
increased upon housing of the assay in the biosensor cavity, this
is expected because glucose must now diffuse across the membrane wall
to reach the assay.
Figure 8
Predicted versus actual glucose response of three assay-filled
biosensors whose cavities were coated with 30 bilayers, corresponding
to a calculated MARD of ∼11%.
Predicted versus actual glucose response of three assay-filled
biosensors whose cavities were coated with 30 bilayers, corresponding
to a calculated MARD of ∼11%.
Conclusions
Toward the development of a CGM with an
extended lifetime and the
ability to be implanted fully subcutaneously, we have reported the
incorporation of a fluorescent competitive binding glucose sensing
assay within the central cavity of a cylindrical “self-cleaning”
membrane. The assay comprised PEGylated-TRITC-ConA and APTS-MT, and
the membrane was a thermoresponsive, electrostatic P(NIPAAm-co-AMPS)/P(NIPAAm-co-NVP) DN hydrogel.
Of central importance was reducing the leaching of the assay from
the membrane cavity. Therefore, an LbL coating comprising PDADMAC+/PSS– bilayers was applied to the biosensor
cavity walls. The negatively charged nature of the membrane imparted
by the AMPS comonomer provided a suitable substrate for the LbL coating.
The membrane’s determined mesh size (∼6.5 to 10 nm)
indicated that the necessary diffusion of glucose (∼0.4 nm)
would not be inhibited and that undesired assay component leaching
would not be expected for PEGylated-TRITC-ConA (∼15 nm) but
would be for APTS-MT (∼1–2 nm). Indeed, even a 30 bilayer
LbL coating was shown not to diminish glucose diffusion, and PEGylated-TRITC-ConA
leaching was limited (<6%) for even uncoated membranes. However,
uncoated membrane cavities permitted the loss of 64% of APTS-MT (under
high glucose concentration conditions) in just 12 h. When the cavity
was coated with 30 bilayers, loss of APTS-MT from the cavity was reduced
to 24%. Such biosensors also exhibited the expected increase in FRET
response upon successive exposure to increasing concentrations of
glucose (50 to 600 mg/dL) over brief time intervals (15 min). Moreover,
these biosensors were able to track changes in physiological glucose
concentrations with a MARD of 11 ± 0.9%. Thus, an LbL coating
shows potential to realize the effective housing of this optical glucose
sensing assay in a self-cleaning membrane. Further refinement of the
LbL coating or the membrane mesh size (e.g., through cross-linking
density) may afford further diminished assay diffusion.
Authors: A Kristen Means; Ping Dong; Fred J Clubb; Molly C Friedemann; Lydia E Colvin; Courtney A Shrode; Gerard L Coté; Melissa A Grunlan Journal: J Mater Sci Mater Med Date: 2019-06-25 Impact factor: 3.896